First patient transfused with Intercept red blood cells in Phase III trial

Cerus (NSDQ:CERS) said today that the 1st patient was transfused in Puerto Rico in a clinical trial comparing red blood cells processed with its Intercept blood system to conventional red blood cells.

Concord, Calif.-based Cerus is developing the Intercept blood system, a pathogen reduction device designed to inactivate a broad range of viruses, bacteria, parasites and leukocytes in donated blood. The 1st stage of the RedeS trial is being conducted in Puerto Rico, where health officials are still very concerned about the effects of the Zika virus epidemic.

Get the full story at our sister site, Drug Delivery Business News.

 

The post First patient transfused with Intercept red blood cells in Phase III trial appeared first on MassDevice.

from MassDevice http://ift.tt/2pPMpME